![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-desktop-header-1gif-4289.gif)
![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-mobgif-81230.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
OATD-01 is an oral, once-daily, first-in-class, and highly selective CHIT1 inhibitor for use in the treatment of pulmonary sarcoidosis. The company has recieved approval to initiate P2 trial.
Lead Product(s): OATD-01
Therapeutic Area: Immunology Product Name: OATD-01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2024
Details:
OATD-01 is an oral, small molecule inhibitor of chitinase-1 (CHIT1), which is being evaluated for the treatment of patients with acute pulmonary sarcoidosis.
Lead Product(s): OATD-01
Therapeutic Area: Immunology Product Name: OATD-01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2024
Details:
OATD-01, is an oral, once-daily, first-in-class highly selective CHIT1 inhibitor for the treatment of pulmonary sarcoidosis. The inhibition of CHIT1 by OATD‑01 has been shown to reduce inflammation & fibrosis.
Lead Product(s): OATD-01
Therapeutic Area: Immunology Product Name: OATD-01
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2023
Details:
OATD-01, is an oral, once-daily, first-in-class highly selective CHIT1 inhibitor for the treatment of pulmonary sarcoidosis. The inhibition of CHIT1 by OATD‑01 has been shown to reduce inflammation & fibrosis.
Lead Product(s): OATD-01
Therapeutic Area: Immunology Product Name: OATD-01
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Galapagos
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2023
Details:
Molecure has regained (at no cost) the full and exclusive rights to the results of all research, pre-clinical and clinical development performed by Galapagos with OATD-01 over the course of the last 18 months.
Lead Product(s): OATD-01
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: OATD-01
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Galapagos
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 23, 2022